11:50 AM
 | 
Jan 22, 2018
 |  BC Extra  |  Company News

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Friday before the deal was announced.

Bioverativ gained $39.68 (62%) to $103.79 on Monday. Sanofi was off 3% on both Euronext and the NYSE.

The deal gives Sanofi marketed drugs Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >